{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:21:46Z","timestamp":1778660506211,"version":"3.51.4"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.2967\/jnumed.109.067587","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T00:45:30Z","timestamp":1255740330000},"page":"1837-1843","source":"Crossref","is-referenced-by-count":18,"title":["Dosimetry of <sup>90<\/sup>Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial"],"prefix":"10.2967","volume":"50","author":[{"given":"Angelika Bischof","family":"Delaloye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Antonescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Louton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Hagenbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2009,10,16]]},"reference":[{"key":"2021051711593971000_50.11.1837.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"2021051711593971000_50.11.1837.2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0020"},{"key":"2021051711593971000_50.11.1837.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"2021051711593971000_50.11.1837.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.12.008"},{"key":"2021051711593971000_50.11.1837.5","unstructured":"Zevalin (90-Y ibritumomab tiuxetan) U.S. prescribing information. Available at: http:\/\/www.zevalin.com\/pdf\/Zevalin_PI_website.pdf. Accessed August 28, 2009."},{"key":"2021051711593971000_50.11.1837.6","unstructured":"Bexxar (tositumomab and iodine I 131 tositumomab) U.S. prescribing information. Available at: http:\/\/us.gsk.com\/products\/assets\/us_bexxar.pdf. Accessed August 28, 2009."},{"key":"2021051711593971000_50.11.1837.7","unstructured":"Zevalin (90-Y ibritumomab tiuxetan) EMEA prescribing information. Available at: http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/zevalin\/H-547-PI-en.pdf. Accessed August 28, 2009."},{"key":"2021051711593971000_50.11.1837.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0207-0"},{"key":"2021051711593971000_50.11.1837.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"2021051711593971000_50.11.1837.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70039-1"},{"key":"2021051711593971000_50.11.1837.11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23236"},{"key":"2021051711593971000_50.11.1837.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"2021051711593971000_50.11.1837.13","first-page":"465","volume":"44","year":"2003","journal-title":"J Nucl Med."},{"key":"2021051711593971000_50.11.1837.14","doi-asserted-by":"publisher","DOI":"10.1089\/108497803765036436"},{"key":"2021051711593971000_50.11.1837.15","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000276"},{"key":"2021051711593971000_50.11.1837.16","first-page":"21S","volume":"39","year":"1998","journal-title":"J Nucl Med."},{"key":"2021051711593971000_50.11.1837.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0372-y"},{"key":"2021051711593971000_50.11.1837.18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","year":"1999","journal-title":"J Clin Oncol."},{"key":"2021051711593971000_50.11.1837.19","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria v2.0 (CTC). Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed August 28, 2009."},{"key":"2021051711593971000_50.11.1837.20","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(91)90080-Z"},{"key":"2021051711593971000_50.11.1837.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.044016"},{"key":"2021051711593971000_50.11.1837.22","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2008.0506"},{"key":"2021051711593971000_50.11.1837.23","doi-asserted-by":"crossref","unstructured":"Chiesa C, Botta F, Coliva A, et al. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin(R)). Eur J Nucl Med Mol Imaging. May 20, 2009 [E-pub ahead of print].","DOI":"10.1007\/s00259-009-1141-x"},{"key":"2021051711593971000_50.11.1837.24","first-page":"260","volume":"44","year":"2003","journal-title":"J Nucl Med."},{"key":"2021051711593971000_50.11.1837.25","first-page":"37S","volume":"40","year":"1999","journal-title":"J Nucl Med."},{"key":"2021051711593971000_50.11.1837.26","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2007.372"},{"key":"2021051711593971000_50.11.1837.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057331"},{"key":"2021051711593971000_50.11.1837.28","first-page":"689","volume":"34","year":"1993","journal-title":"J Nucl Med."},{"key":"2021051711593971000_50.11.1837.29","first-page":"2000","volume":"44","year":"2003","journal-title":"J Nucl Med."},{"key":"2021051711593971000_50.11.1837.30","first-page":"12P","volume":"50","year":"2009","journal-title":"J Nucl Med."},{"key":"2021051711593971000_50.11.1837.31","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.035"},{"key":"2021051711593971000_50.11.1837.32","doi-asserted-by":"publisher","DOI":"10.1089\/108497802760363222"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.109.067587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T19:19:27Z","timestamp":1621279167000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.109.067587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,16]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,10,29]]},"published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.2967\/jnumed.109.067587"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.109.067587","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,16]]}}}